Study of immunological response to nucleic acid delivery system

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H04639
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Physical pharmacy
• Research Institution: The University of Tokushima
• Principal Investigator: ISHIDA Tatsuhiro 徳島大学, 大学院医歯薬学研究部(薬学系), 教授 (50325271)
• Co-Investigator(Kenkyū-buntansha): 南川 典昭 徳島大学, 大学院医歯薬学研究部(薬学系), 教授 (40209820) ; 異島 優 徳島大学, 大学院医歯薬学研究部(薬学系), 准教授 (00457590) ; 清水 太郎 徳島大学, 大学院医歯薬学研究部(薬学系), 特任助教 (30749388) ; 安藤 英紀 徳島大学, 大学院医歯薬学研究部(薬学系), 特任助教 (00735524) ; 鵜川 真実 徳島大学, 大学院医歯薬学研究部(薬学系), 特任助教 (50735511)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 核酸 / 免疫 / Anti-PEG IgM / リポソーム / DDS

Outline of Final Research Achievements

In this study, we reported that immunostimulatory siRNA/pDAN-containing PEGylated lipoplex (PEGylated siRNAlipoplex) activates the immune system, resulting in the enhanced production of anti-PEG IgM. We revealed the contribution of toll-like receptor 7/9 to activate the innate immune system, respectively. A strategy to evade B cell-intrinsic TLR7/9 activation by siRNA/pDNA, such as chemical modification, may overcome immunological barriers to PEGylated liposome-based nucleic acid therapeutics. In addition, we showed PEG in the cosmetics may trigger anti-PEG IgM production in human. Our study gives the researchers valuable information which is useful to develop PEGylated nucleic acid based therapeutics.

Free Research Field

薬剤学